

**AMENDMENT TO MR. TAUZIN'S AMENDMENT**  
**OFFERED BY MR. ALLEN**

**(Page & line nos. refer to Chairman's Mark of June 17, 2003)**

In section 1807(i) of the Social Security Act (as proposed to be inserted by section 105) add at the end the following new paragraph:

1           “(7) GUARANTEE OF LOWEST PRICE FOR DRUGS FOR  
2           BENEFICIARIES.—

3           “(A) IN GENERAL.—Each participating manufac-  
4           turer of a covered outpatient drug shall enter into ar-  
5           rangements with eligible entities offering the endorsed  
6           programs under this section to make available for pur-  
7           chase by such entities such covered outpatient drug at  
8           the price described in subparagraph (B). Those entities  
9           shall make available such prescription drugs to medi-  
10          care beneficiaries enrolled under the endorsed program  
11          at that price.

12          “(B) DESCRIPTION OF PRICE.—The price at which  
13          a participating manufacturer shall make a covered out-  
14          patient drug available for purchase by a pharmacy is  
15          a price no greater than the manufacturer's average for-  
16          eign price.

17          “(C) DEFINITIONS OF PARTICIPATING MANUFAC-  
18          TURER.—In this paragraph:

19               “(i) PARTICIPATING MANUFACTURER.—The  
20               term ‘participating manufacturer’ means any man-  
21               ufacturer of drugs or biologicals that, on or after  
22               the date of the enactment of this section, enters  
23               into a contract or agreement with the United  
24               States for the sale or distribution of covered out-  
25               patient drugs to the United States.

26               “(ii) AVERAGE FOREIGN PRICE.—

## 2

1           “(I) IN GENERAL.—The term ‘average for-  
2           eign price’ means, with respect to a covered  
3           outpatient drug, the average price that the  
4           manufacturer of the drug realizes on the sale  
5           of drugs with the same active ingredient or in-  
6           gredients that are consumed in covered foreign  
7           nations, taking into account—

8           “(aa) any rebate, contract term or  
9           condition, or other arrangement (whether  
10          with the purchaser or other persons) that  
11          has the effect of reducing the amount real-  
12          ized by the manufacturer on the sale of the  
13          drugs; and

14          “(bb) adjustments for any differences  
15          in dosage, formulation, or other relevant  
16          characteristics of the drugs.

17          “(II) EXEMPT TRANSACTIONS.—The Sec-  
18          retary may, by regulation, exempt from the cal-  
19          culation of the average foreign price of a drug  
20          those prices realized by a manufacturer in  
21          transactions that are entered into for charitable  
22          purposes, for research purposes, or under other  
23          unusual circumstances, if the Secretary deter-  
24          mines that the exemption is in the public inter-  
25          est and is consistent with the purposes of this  
26          paragraph.

27          “(iii) COVERED FOREIGN NATION.—The term  
28          ‘covered foreign nation’ means Canada, France,  
29          Germany, Italy, Japan, and the United Kingdom.